Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Bluemn, Eric G., Coleman, Ilsa M., Lucas, Jared M., Coleman, Roger T., Hernandez-Lopez, Susana, Tharakan, Robin, Bianchi-Frias, Daniella, Dumpit, Ruth F. +19 more·2017·Cancer Cell
DOI 10.1016/j.ccell.2017.09.003

Cited by (744)

Items 701–744 of 744

  1. Role of long non-coding RNAs in prostate cancer progression
    Rocco Cipolla · 2023
  2. Spatiotemporal profiling reveals the role of inflammatory niche in driving prostate cancer
    Abbas Nazir, Hanchen Wang, Ziyu Lu, Jeffrey Lau, Frank Peale, Rajiv Jesudason, Kelli A. Connolly, Žaneta Andrusivová, Julia Lau, Sarah Gierke et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  3. Molecular insights into DDX3X–androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer
    Han Zhang, Teresa T. Liu, Feixuan Wu, Avan N Colah, Emily A. Ricke, Lingjun Li, Andrea A. Putnam, William A. Ricke · 2026 · Oncogene
  4. Treatment Approaches and Future Directions for Neuroendocrine Prostate Cancer and Other Aggressive Variant Prostate Cancers
    Alex C. Hughes, Laura S Graham · 2026 · Advances in Oncology
  5. Advanced nanomedicines to target prostate cancer cells: emerging molecular tools and future clinical prospects
    Omar Abboud, Muhammad Sohail · 2026 · International Journal of Pharmaceutics
  6. The emerging role of prostate-specific membrane antigen–targeted radioligand therapy in metastatic hormone-sensitive prostate cancer
    Philipose Getachew Mulugeta, Tanya B. Dorff, Jason M. Hafron, Mai Anh Huynh, Alicia Katherine Morgans, Ashely E. Ross, Rana R. McKay · 2026 · The Oncologist
  7. Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.
    C. Choi, Matthew Labriola, N. Henderson, Alec Chu, Clara Hwang, Pedro C. Barata, F. Cackowski, Amanda Broderick, R. Mckay, M. Bilen et al. · 2026 · Prostate Cancer and Prostatic Diseases
  8. Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer
    Lisha G. Brown, Ilsa M. Coleman, Tony LH Chu, Erolcan Sayar, Radhika A. Patel, Brian P. Hanratty, Mohamed Adil, Dapei Li, Yongtao Li, Holly M. Nguyen et al. · 2026 · Neoplasia
  9. Single-Cell Analysis Reveals Pre-Existing Basal-Associated Epithelial States in Metastatic Hormone-Naïve Prostate Cancer
    Ryuta Watanabe, Mami Chosei, Tomohisa Sakaue, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika · 2026 · International Journal of Molecular Sciences
  10. CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer
    Ava Safaroghli‐Azar, Travis Croft, Laychiluh Bantie Mekonnen, Jimma Likisa Lenjisa, Maja Dickel, Raj K. Shrestha, Samyukta Sita, Nicholas Choo, Michael J. Roach, Sunita K. C. Basnet et al. · 2026 · Journal of Experimental & Clinical Cancer Research
  11. 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer
    Songyan Qi, Scott M. Dehm · 2026 · Endocrinology
  12. Mechanisms of resistance to androgen deprivation therapy in prostate cancer
    Imane Bensalim, Lahcen Belyamani, Saber Boutayeb, Ilhame Bourais · 2026 · Molecular Aspects of Medicine
  13. Thermodynamic Quality Control Reshapes Spatially Resolved Metabolic Flux Predictions in Prostate Cancer
    Mohammad Reza Zargar, Sunayana Malla, Rajib Saha, Ratul Chowdhury · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  14. A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator that promotes prostate cancer proliferation
    Raymond J. Kostlan, John T. Phoenix, Audris Budreika, Carli D. Deegan, Marina G. Ferrari, Elise T Warren, Pushpinder Bawa, Charles S Rogers, Divya Dureja, M Obaidulla Ibne Ali et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  15. Tumor-associated macrophages and lineage plasticity in prostate cancer: from established myeloid programs to emerging spatial hypotheses
    Jia Li, Jinling Li, Y Zhao, Yuanqi Yu, Xiaolu Cui · 2026 · Frontiers in Immunology
  16. An Integrated Preclinical Platform for Lethal Neuroendocrine Prostate Cancer from Rapid Autopsy Bone and Liver Metastases
    Borum Ryu, Thomas C. Caffrey, Sriya Sridhar, Catherine S. Johnson, Ramia J. Salloom, Kabhilan Mohan, Grace Waldron, Amanda Robotham, Ethan M Wilcox, Diane L. Costanzo-Garvey et al. · 2026 · SSRN Electronic Journal
  17. Enzalutamide promotes an early plasticity-associated transcriptional state without terminal neuroendocrine differentiation in prostate cancer cells
    Ryuta Watanabe, Mami Chosei, Haruna Arai, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika · 2026 · Frontiers in Oncology
  18. The FGFRL1–FASN axis regulates neuroendocrine lineage transdifferentiation by modulating fatty acid synthesis in AR pathway-independent prostate cancer
    Yupeng Chen, Jiarun Lai, Jian Chen, Ziqing Zhou, Qianfeng Xu, Rui Zhou, Jinchuang Li, Yusen Long, Ailiyaerjiang Wureyimu, Jiaming Su et al. · 2026 · Cancer Letters
  19. Development and Validation of a Treatment-Specific Prognostic Model for Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with First-Line Apalutamide: A Multicenter Real-World Study
    Shin Kobayashi, Takuma Narita, Kotona Miyauchi, Shun Morishita, Naoki Fujita, Daiki Kikuchi, Noriyuki Abe, Miyu Ohtani, Naoki Wada, Shingo Hatakeyama et al. · 2026 · Research Square
  20. The Great Escape: the systems biology of endocrine resistance and lineage plasticity
    Christo Philip C. Dragnev, Zirui Fu, Sida Huang, Curtis J. Perry, Adriana Matutino Kahn, Michaela Ann Dinan, Wei Shen Tan, Michael S. Leapman, David A. Braun, Joshua Warrick et al. · 2026 · Endocrine Related Cancer
  21. SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer
    Zhen Zhu, Yuyong Shen, Xingjun He, Ming Zhou · 2026 · Frontiers in Pharmacology
  22. Comparative Assessment of METastasis Reporting and Data System for Prostate Cancer Versus Prostate Cancer Clinical Trials Working Group 3 Criteria in Assessing Treatment Response in Patients with Metastatic Castration-resistant Prostate Cancer
    Luca Russo, Ossian Longoria, Silvia Bottazzi, Núria Porta, Katie Biscombe, Samuel Joseph Withey, Giacomo Avesani, Katarzyna Abramowicz, Matthew D. Blackledge, Luca D’Erme et al. · 2026 · European Urology Open Science
  23. Reprogramming the Evolution of High-Risk Prostate Cancer: Multidisciplinary Strategies to Delay Castration Resistance
    Younghun Sim, Jae Won Choi, Dong Seob Kim, Jeong Hyun Kim, Sung Goo Yoon, Jung Ki Jo · 2026 · Journal of Clinical Medicine
  24. IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states
    Dimitrios Doultsinos, Ingrid Tomljanović, Eleftherios Pilalis, Sophia M. Abusamra, Mohammed Alshalalfa, Romuald Parmentier, Vidhula R. Ahire, Imogen Bridges, Sandy Figiel, Joanna Hester et al. · 2026 · EMBO Molecular Medicine
  25. RUNX1T1 drives stem-like small-cell neuroendocrine prostate cancer identity
    Ziqin Wang, Hyeryeon Jung, Changhyeon Hong, Nancy Chen, Yunsol Jo, Issac Jung, Taeeun Kim, Gina Lee, Keaton Chien, Ming Chen et al. · 2026 · Frontiers in Cell and Developmental Biology
  26. Advances in understanding the tumor microenvironment of neuroendocrine prostate cancer
    Nan Yao, Qixing Yang, Pengkang Chang, Yangcai Wang, Hao Li, Ronghua Wu, Ji Zheng, Weihua Fu · 2026 · Frontiers in Oncology
  27. Neuromedin U ‘innervation’ reprograms myeloid immunosuppression in neuroendocrine prostate cancer
    Michela Perego, Jozef Madžo, Andrew V. Kossenkov, Firdevs Cansu Atilgan, Marcella Tazzari, Maria Maddalena Tumedei, Francesco Limarzi, Cristian Lolli, Giorgia Gurioli, Alessandro Fatatis et al. · 2026 · Oncogene
  28. CXCR4-centred signalling network rewiring distinguishes primary and metastatic prostate cancer: A systems-level digital twin framework
    Radosław Dzik, Joanna Chwał, Ewaryst Tkacz · 2026 · European Journal of Cell Biology
  29. Cryo-EM structure-based discovery of etravirine as a specific inhibitor of PRMT5/pICln protein-protein interaction for prostate cancer treatment
    Zhixia Chi, Xueyong Xu, Zhihang Shen, Xuehong Deng, Bennett D. Elzey, Chenglong Li, Wen Jiang, Chang‐Deng Hu · 2026 · Journal of Enzyme Inhibition and Medicinal Chemistry
  30. Castration-resistant prostate cancer as an adaptive tumor ecosystem: coupling tumor evolution with microenvironmental reprogramming
    Siliang Wang, Xinyi Xu, Minghuang Xu, Yuang Wei, 乔云晓, Xiaowen Song, Chuang Xie, Chunmei Zhou, Fuwen Yuan · 2026 · Cancer and Metastasis Reviews
  31. TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis
    Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu · 2026 · Clinical and Translational Medicine
  32. Transcriptomic profiling of prostate cancer treated with radiation versus combined androgen deprivation therapy: Machine learning based identification of prognostic biomarkers
    Atish Ghosh, Norine Dsouza · 2026 · In Silico Research in Biomedicine
  33. Follistatin drives AR-independent prostate cancer through BMP signaling inactivation and microenvironmental remodeling
    Xiaoxian Shi, Zuyan Fan, Min Qu, Chunjie Lin, Zhiheng Ji, Caiwei Tan, Biqi Dai, Rushan Chen, Yixuan Du, Yizhong Bao et al. · 2026 · Proceedings of the National Academy of Sciences
  34. DiCE-Ex: a web server for network-based differential-centrality gene exploration
    Sandali D. Lokuge, Sheng Liu, Marissa Shang, Kai Yang, Stephanie M. Ware, Lei Yang, Xin Lü, Jun Wan · 2026 · Nucleic Acids Research
  35. EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer
    Beatriz German, Katherine L. Morel, Teia Noel, Nadia Boufaied, Deborah L. Burkhart, Sujun Chen, Felipe Dezem, Xintao Qiu, Henry W. Long, Kun-Lin Ho et al. · 2026 · Cell Reports Medicine
  36. Establishment and characterization of LNCaP-TR-BoM, a bone metastasis-derived prostate cancer cell line with an intermediate AR-attenuated phenotype
    Adrian Chao, Xin Lü · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  37. Non-conventional histologies of prostate cancer: from morphology to biology-driven precision oncology
    Fabiano Flauto, Giuseppe Neola, Alessia Cimadamore, Michele Maffezzoli, Akash Maniam, Sarah Scagliarini, Fabio Calabrò, Luigi Formisano, Pasquale Rescigno, Giuseppe Luigi Banna · 2026 · The Oncologist
  38. tRNA dosage regulates lineage dependency and resistance in prostate cancer
    Yeon Soo Kim, Sonali Arora, Dave Young, Ava Tsou, Amy Shiuan, Cynthia L. Wladyka, Dmytro Rudoy, Jin Yeong kim, Jennifer A. Waters, Samantha L. Schuster et al. · 2026 · Nature
  39. Targeting the HIF-1α–BSG metabolic circuit reverses enzalutamide resistance in prostate cancer
    Xiuchen Guo, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Yongjiang Yu · 2026 · Cellular Signalling
  40. Molecular features of prostate cancer with neuroendocrine differentiation
    Behtash Ghazi Nezami, Xiaoqi Lin · 2026 · Seminars in Diagnostic Pathology
  41. A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate Cancer
    Sriya Sridhar, Kabhilan Mohan, Smitha Kizhake, Amarnath Natarajan, David L Kelly, Grinu Mathew · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Lineage plasticity–driven immunometabolic state transitions in advanced prostate cancer: biomarkers and therapeutic stratification
    Haowen Wu, Wei Zhang, Xin Yan, Kai Ma, Manuel Colucci, Qiang G Dong, Pan Song · 2026 · Seminars in Immunopathology
  43. BindingDB Entry 50016189: Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
    BindingDB · 2023 · UC San Diego
  44. BindingDB Entry 50019182: Physachenolide C is a Potent, Selective BET Inhibitor.
    BindingDB · 2024 · UC San Diego